A Novel Immunotherapy Approach for the Treatment of COVID-19

Corvus Pharmaceuticals: FDA Granted IND Application for COVID-19 Trial
The United States FDA granted approval of Corvus Pharmaceuticals (CRVS) investigational new drug (IND) application for a COVID-19 trial.

Corvus announced the beginning of the Phase 1 study that intends to enroll up to 30 patients. The . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.